Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Metastatic Pancreatic Adenocarcinoma × BKT140 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Metastatic Pancreatic Adenocarcinoma 1

Interventions

Gemcitabine 4 pembrolizumab 2 Leucovorin 2 Irinotecan 2 Fluorouracil 2 Albumin-Bound Paclitaxel 2 4-fluorobenzoyl-TN-14003 2 regorafenib 1 olaparib 1 irinotecan sucrosofate 1 ibrutinib 1 adavosertib 1 Paclitaxel 1 PEGPH20 1 Oxaliplatin 1 Drug Therapy 1 Docetaxel 1 Cisplatin 1 Capecitabine 1 BKT140 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02907099 2025-02-19

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 2 Completed

20 enrolled 12 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡